Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Autonomix Medical, Inc. ( (AMIX) ) just unveiled an announcement.
On November 18, 2025, Autonomix Medical, Inc. entered into a Securities Purchase Agreement with an institutional investor to sell pre-funded warrants and Series C Warrants in a private placement. The transaction, which closed on November 19, 2025, raised approximately $5.0 million in gross proceeds, which the company plans to use for working capital and general corporate purposes. The agreement restricts the company from entering certain transactions involving its equity securities for a specified period, and it has committed to filing a registration statement for the resale of the underlying common stock.
The most recent analyst rating on (AMIX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Autonomix Medical, Inc. stock, see the AMIX Stock Forecast page.
Spark’s Take on AMIX Stock
According to Spark, TipRanks’ AI Analyst, AMIX is a Underperform.
Autonomix Medical, Inc. struggles with severe financial performance issues due to zero revenue and negative cash flow, despite low debt levels. Technical analysis suggests some short-term momentum, but a longer-term downtrend persists. Valuation is significantly impacted by negative earnings and no dividend yield. Positive trial outcomes present a potential opportunity but are insufficient to offset the substantial financial challenges.
To see Spark’s full report on AMIX stock, click here.
More about Autonomix Medical, Inc.
Average Trading Volume: 5,276,589
Technical Sentiment Signal: Sell
Current Market Cap: $7.92M
For an in-depth examination of AMIX stock, go to TipRanks’ Overview page.